R
R. Stephens
Publications - 5
Citations - 601
R. Stephens is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 5 publications receiving 601 citations.
Papers
More filters
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,D. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).
Alexander R. Lyon,Teresa López-Fernández,Liam Couch,Riccardo Asteggiano,Marianne C. Aznar,Jutta Bergler-Klein,Giuseppe Boriani,Daniela Cardinale,Raul Cordoba,Bernard Cosyns,D Cutter,Evandro de Azambuja,W. De Boer,Susan Dent,Dimitrios Farmakis,Sofie Gevaert,Diana A. Gorog,A. Herrmann,Daniel J. Lenihan,Javid Moslehi,Brenda Moura,Sonja S Salinger,R. Stephens,Thomas M. Suter,Sebastian Szmit,Juan Tamargo,Paaladinesh Thavendiranathan,Carlo G. Tocchetti,P. Van Der Meer,Helena J H van der Pal +29 more
Journal ArticleDOI
Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
Andrew Davies,Louise Stanton,Josh Caddy,Sharon Barrans,Sam Wilding,Geoff Saunders,Christoph Mamot,Urban Novak,Andrew McMillan,Paul Fields,Graham P. Collins,R. Stephens,Francesco Cucco,Chulin Sha,Moniek van Hoppe,Reuben Tooze,Matthew A. Care,Gareth Griffiths,Anna Schuh,Ming-Qing Du,David R. Westhead,C. Burton,Peter Johnson +22 more
TL;DR: The REMoDL-B trial as mentioned in this paper compared R-CHOP versus RB-ChOP in patients with diffuse large B-cell lymphoma (DLBCL) stratified by cell of origin determined by gene expression profile (GEP).
Journal ArticleDOI
European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment
G Andrew Lee,Suleman Aktaa,E. Baker,Chris P Gale,Israa F. Yaseen,Geeta Gulati,Riccardo Asteggiano,Sebastian Szmit,Alain Cohen-Solal,A. H. Abdin,Woijciech Jurczak,Pilar Garrido Lopez,Aaron L. Sverdlov,Carlo G. Tocchetti,Ana Barac,Iris Parrini,Pepe Zamorano,Zaza Iakobishvili,Radek Pudil,Lina Badimon,Anna M. Kirby,Anne H. Blaes,D. E. Farmakis,Giuseppe Curigliano,R. Stephens,Alexander R. Lyon,Teresa López-Fernández +26 more
TL;DR: The ESC Cardio-Oncology Quality Indicator (QI) developed by the European Society of Cardiology (ESC) aims at quantifying and improving the adherence to guideline-recommended clinical practice and improving patient outcomes as mentioned in this paper .
Journal ArticleDOI
Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up
Andrew Davies,Sharon Barrans,Louise Stanton,Josh Caddy,Sam Wilding,Geoff Saunders,Christoph Mamot,Urban Novak,Andrew McMillan,Paul Fields,Graham P. Collins,R. Stephens,Francesco Cucco,Chulin Sha,Moniek van Hoppe,Reuben Tooze,John R. Davies,Gareth Griffiths,Anna Schuh,C. Burton,David R. Westhead,Ming-Qing Du,Peter Johnson +22 more
TL;DR: The REMoDL-B phase III adaptive trial as mentioned in this paper compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHop + bortezomib (RB-CHOPS) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtypes.